B7-H1 is a recently identified B7 family member that, along with one of its receptors, programmed death-1 (PD-1), has been involved in multiple immunopathologic scenarios. However, the nature of B7-H1 and PD-1 in human hepatocellular carcinoma (HCC) remains poorly defined. We investigated the expression and functional relevance of this pathway in patients with HCC. We showed that B7-H1 expression on Kupffer cells (KC) was increased in tumor tissues compared with surrounding nontumor liver tissues in patients with HCC and this correlated with poorer survival. Coculture of HCC cells with monocytes showed that tumor-associated interleukin-10 contributed to the induction of B7-H1 in the HCC environment. We further observed that the levels of PD-1 + CD8 + T cells were higher in tumor tissues than in nontumor tissues. B7-H1 + KCs and PD-1 + T cells were colocalized in the HCC stroma. PD-1 + CD8 + T cells had decreased proliferative ability and effector function as shown by reduced granule and cytokine expression compared with PD-1 À T cells. Importantly, blocking KC B7-H1 interaction with PD-1 + CD8 + cells using neutralizing antibodies recovered effector T-cell function. Our data indicate that the B7-H1/PD-1 axis contributes to immune suppression in human HCC, with blockade of this pathway carrying important therapeutic implications. [Cancer Res 2009;69(20):8067-75] 
Introduction
Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and is the second most common cause of cancer-related deaths in the world. Although resection and transplantation are possible therapeutic options, 5-year recurrence rates following resection can exceed 50% (1) . Several variables affect the risk of recurrence following resection, including tumor size, tumor number, and vascular invasion. However, the role of tumor immunity is increasingly being recognized as being important to controlling tumor progression or recurrence in cases of breast, ovarian, and pancreatic cancers along with many others (2) . Recently, HCC recurrence and stage is independently predicted by the degree of CD8 + tumor-infiltrating T cells (3) . CD8 + CTLs are the major effectors against tumor cells (4) . However, the progression of HCC and other tumors despite the presence of infiltrating CD8 + T cells stresses the pathologic significance of the regulatory mechanisms within the tumor microenvironment.
Recent evidence suggests that CD8
+ T cells may become dysfunctional or functionally exhausted within the tumor microenvironment (5) .
Programmed death-1 (PD-1; CD279) may have an important role in the exhaustion of CD8 + T cells in infectious diseases (6, 7) . Functionally exhausted CD8 + T cells express high levels of PD-1. PD-1 has two ligands with distinct expression patterns: B7-H1 [programmed death ligand 1 (PD-L1); CD274] and B7-DC (PD-L2; CD273). B7-H1 is expressed on resting T cells, B cells, dendritic cells, and macrophages and is further up-regulated on activation (8) . B7-H1, which acts as an antiapoptotic receptor, is also expressed on some tumor cells (9) . In contrast, B7-DC is expressed only on DC and macrophages following induction (10) . Ligation of PD-1 by B7-H1 transduces a negative signal when transmitted simultaneously with T-cell receptor (TCR) signaling. This negative regulatory function is accomplished through the cytoplasmic domain of the molecule, which recruits intracellular phosphatases SHP-1 and SHP-2 (6) . The recruitment of these phosphatases to the membrane leads to the dephosphorylation of several key signaling intermediates and thus the attenuation of TCR-mediated signals and T-cell activation. It has been shown that B7-H1/PD-1 interactions contribute to the suppression of antiviral immunity in liver or antitumor immunity (11) (12) (13) (14) (15) (16) . However, little is known about the functional relevance and mechanism of B7-H1 and PD-1 in human HCC.
The liver is an immunologically privileged site as studied in oral tolerance and transplantation models (17) . Tolerogenic or suppressive antigen-presenting cells (APC), numerous in liver tissue, are thought to control tolerogenic phenotypes. Recently, B7-H1 was shown to be expressed on hepatocytes and liver residential APCs, contributing to deletion of intrahepatic T cells, preventing hepatic autoimmunity, and suppressing antiviral immune responses in animal models (18, 19) . Given the relative paucity of data on the HCC microenvironment, we studied tumor tissues and surrounding nontumor liver tissues in HCC patients undergoing surgical resection and investigated the expression and functional relevance of B7-H1 and PD-1 in the human HCC microenvironment. Evidence is provided that Kupffer cells (KC) primarily express B7-H1 in human HCC and mediate decreased effector function via interaction with PD-1 on effector T cells. Furthermore, this suppression seems to be reversible following disruption of these interactions, carrying potential immunotherapeutic implications.
2002 were studied. These tissues were analyzed for tumor tissue B7-H1 expression by immunohistochemistry. The clinical characteristics of all patients are summarized in Flow cytometry. Anti-human CD3, CD4, CD8, CD11c, CD14, CD45, CD123, HLA-DR, B7-H1, PD-1, Foxp3, granzyme B, perforin, IFNg, and tumor necrosis factor a (TNFa) antibodies (BD Biosciences) were used in FACS and compared with isotype antibody controls as appropriate. Antihuman Ki67 (BD Biosciences) staining was used to identify proliferating cells. For intracellular cytokine staining, cells were exposed for 4 h with phorbol 12-myristate 13-acetate (PMA; 50 ng/mL; Sigma), ionomycin (500 ng/mL; Sigma), GolgiStop (1 AL/1.5 mL; BD Biosciences), and GolgiPlug (1 AL/mL; BD Biosciences) as previously described (20) followed by surface and intracellular staining of various cytokines according to the manufacturer's instructions (BD Biosciences).
Immunohistochemistry. Fluorescence immunohistochemistry was performed on 8-Am cytosections of tissues. Briefly, tissues were stained as indicated with primary antibodies, including mouse anti-human B7-H1 (clone MIH1, IgG1, 1:100; BD Biosciences), mouse anti-human CD68 (clone Y1/82A, IgG2b, 1:100; BD Biosciences), mouse anti-human PD-1 (clone NAT, IgG1, 1:200; Abcam), goat anti-human PD-1 (IgG, 1:100; R&D Systems, Inc.), and rat anti-human CD8 (clone YTC182.20, IgG2b, 1:200; Abcam). Secondary antibodies were Alexa Fluor 568-conjugated goat antimouse IgG1, Alexa Fluor 488-conjugated goat anti-mouse IgG2b, Alexa Fluor 488-conjugated donkey anti-goat IgG, Alexa Fluor 568-conjugated goat anti-mouse IgG1, or Alexa Fluor 488-conjugated goat anti-rat IgG (all 2 Ag/mL; Molecular Probes). 4 ¶,6-Diamidino-2-phenylindole (DAPI; Invitrogen) was used for nuclear staining. Fluorescent expression was evaluated with the Leica DM 5000B fluorescence microscope and compared with antibody isotype controls. Positive cells were quantified by ImagePro Plus software (Media Cybernetics) and expressed as the mean number of positive cells F SE in 10 high-powered fields. For survival analysis, experiments were performed by two independent observers who were blinded to the clinical outcome. At low power field (Â100), the tissue sections were screened using a Leica DM IRB inverted research microscope (Leica Microsystems), and the five most representative fields were selected. Thereafter, to evaluate the density of B7-H1 + cells, the respective areas of tumor tissue were measured at Â400 magnification, and the nucleated cells positive for B7-H1 in each area were counted and expressed as number of cells per field. /mL) from blood of healthy donors were plated to the lower chambers. Recombinant human interleukin-10 (IL-10; 10 ng/mL; R&D Systems) or monoclonal antibody against human IL-10 (500 ng/mL; R&D Systems) were added to select wells in the upper chamber. After 48 h, CD14 + cells were harvested and B7-H1 expression was determined by FACS. Where indicated, supernatants from Transwell experiments and cultured cells were checked by human IL-10 ELISA kit (R&D Systems).
Western blot analysis and real-time reverse transcription-PCR. Single-cell suspensions from HCC tumor tissues and surrounding liver tissues were used for Western blot analysis and real-time reverse transcription-PCR (RT-PCR). Briefly, for Western blot analysis, whole-cell lysates were prepared by incubating cells in ice-cold lysis buffer [20 mmol/L Tris (pH 7.8), 2 mmol/L EDTA, 50 mmol/L NaF, 1% Triton X-100, 5 Ag/mL leupeptin, 5 Ag/mL pepstatin, 0.5 mmol/L phenylmethylsulfonyl fluoride]. The lysates were then centrifuged at 14,000 Â g for 15 min at 4jC and assayed for protein with the Bio-Rad protein assay reagent. Equal amounts of protein were resolved by SDS-PAGE and transferred to nitrocellulose membranes. The following antibodies for Western blots were used: mouse anti-human IL-10 (clone 25209, IgG2b, 1:1,000; R&D Systems) and mouse anti-human h-actin (clone AC-15, IgG1, 1:2,000; Sigma). Images were visualized with an enhanced chemiluminescence detection system (Amersham Biosciences; ref. 21 ). For RT-PCR, total RNA from tumor tissues and liver tissue as indicated was isolated using RNeasy kits (Qiagen). cDNA synthesis was performed using SuperScript One-Cycle cDNA kit (Invitrogen). The cDNA served as a template in real-time PCR using Fast SYBR Green Master kit (Applied Biosystems). The following primers for RT-PCR were used: human IL-10 primers, 5 ¶-CATTCTTCACCTGCTCCAC-G-3 ¶ (sense) and 5 ¶-AACCTGCCTAACATGCTTCG-3 ¶ (antisense; ref . 22); human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers, 5 ¶-CTGCCCCCTCTGCTGATG-3 ¶ (sense) and 5 ¶-TCCACGATACCAAAGTTG-TCATG-3 ¶ (antisense; ref. 23 ). All reactions were performed in triplicate. IL-10 mRNA expression of different group specimens was normalized to GAPDH. Relative IL-10 mRNA levels are presented as unit values of 2
, where C t is the threshold cycle value defined as the fractional cycle number at which the target fluorescent signal passes a fixed threshold above baseline.
Proliferation assay. After 5 d of coculture, T cells were pulsed with IFN; enzyme-linked immunospot assay. MultiScreen filtration plates (96-wells per plate; Millipore) were coated with 100 AL/well of 4 Ag/mL purified anti-human IFNg antibody (clone NIB42; BD Pharmingen) overnight at 4jC and then incubated for 90 min at room temperature with 150 AL/well of 1% bovine serum albumin (Sigma) in PBS. CD8 + cells (1 Â 10 5 /100 AL/well) and CD14 + cells (5 Â 10 4 /100 AL/well) from tumor tissues were placed into 96-well round-bottomed cluster plates in the presence of anti-human CD28 (1.2 Ag/mL, clone CD28.2; BD Biosciences) for 5 d at 37jC, 5% CO 2 in presence or absence of anti-human B7-H1 (clone 5H1, 5 Ag/mL) or anti-human PD-1 (clone M3, 5 Ag/mL) antibody. Then, all the cells were transferred to MultiScreen filtration plates and incubated for 48 h in the presence of HCC tumor cells lysate ( from 1 Â 10 4 per well) at 37jC, 5% CO 2 . PMA (1 ng/mL)-treated and ionomycin (0.5 Ag/mL)-treated CD8 + effector cells served as a positive control (f100 spots per well; data not shown). Plates were washed and incubated overnight at 4jC with 100 AL/well of 4 Ag/mL of biotinylated rat antihuman IFNg antibody (clone 4S.B3; BD Pharmingen) followed by a 90-min incubation with 100 AL/well anti-biotin alkaline phosphatase (Vector Laboratories, Inc.) diluted 1:1,000. Spots were visualized with 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium alkaline phosphatase substrate and counted using the ImmunoSpot analyzer (Cellular Technology Ltd.).
Statistical analysis. Data are presented as the mean F SE. Significant differences between groups were analyzed using Wilcoxon matched-pairs rank test for nonparametric data or one-way ANOVA test, where appropriate. P values of <0.05 were considered statistically significant. For survival analysis, survival curves were compared by the Kaplan-Meier method and the log-rank test, and survival was measured in months from resection to the last review. All analyses were done using Statistical Package for the Social Sciences v12.0 software.
Results
B7-H1 expression on APC subsets in human HCC. We analyzed the prevalence and phenotype of APC subsets within paired tumor tissues and surrounding liver tissues in patients with HCC (n = 20 (Fig. 1A) . We next examined the expression of B7-H1 on these APC subsets. mDCs and pDCs expressed negligible levels of B7-H1 ( Supplementary Fig. S1 ). Similar to our previous observation on ovarian cancer-associated macrophages (12), KCs were the predominant B7-H1 + population in HCC microenvironment. The percentage of B7-H1 + KCs was higher in tumor tissues than surrounding liver tissues [17.6 F 4.1% versus 7 F 2.7%, n = 15, P < 0.05, both by percentage of cells and mean fluorescence intensity (MFI)] when compared with antibody isotype controls ( Fig. 1B;  Supplementary Fig. S1 ). Further, the levels of B7-H1 expression on tumor-associated KCs were significantly higher than that on other APC subsets in different compartments (Supplementary Fig. S1 ). Using immune fluorescence staining, we confirmed that CD68 + KCs expressed more B7-H1 in HCC tumor tissues (Fig. 1C, a) than in surrounding nontumor (Fig. 1C, b) and normal liver tissues (Fig. 1C, c) . Cells were negative for staining with isotype control antibodies (Fig. 1C, d) .
To evaluate whether B7-H1 expression is a prognostic factor for survival after HCC tumor resection, 71 patients were divided into a low B7-H1-expressing and a high B7-H1-expressing group by using the median value of B7-H1 + cell density in tumor tissues on immunohistochemistry. Overall, the high B7-H1-expressing group experienced worse survival when compared with the lower B7-H1-expressing group following log-rank analysis (Fig. 1D) . The data indicate that high levels of B7-H1 are expressed in the HCC microenvironment, which correlated with worse prognosis, and that B7-H1 is primarily expressed on KCs in HCC tumor tissues.
Tumor-associated IL-10 induced B7-H1 expression on KCs. Our previous work in human ovarian carcinoma indicated that tumor-associated IL-10 can up-regulate B7-H1 expression (15) . Therefore, we examined the potential factors in the HCC microenvironment contributing to KC B7-H1 up-regulation. We cocultured blood CD14 + monocytes from healthy donors with primary HCC tumor cells or Hep G2 cells. Monocyte B7-H1 expression was significantly increased in the coculture with HCC tumor cells or Hep G2 cells (Fig. 2A) . Increased levels of IL-10 were also detected in the cocultures (Fig. 2B) . Additionally, both mRNA and protein expression of IL-10 were increased in primary HCC tumor tissues compared with surrounding liver tissues (Fig. 2C and  D) . The addition of recombinant IL-10 moderately induced B7-H1 expression on monocytes ( Fig. 2A) , whereas neutralizing antibody against IL-10 significantly blocked monocyte B7-H1 expression induced in coculture. These results suggest that HCC-associated IL-10 production may contribute to increased KC B7-H1 expression in the HCC microenvironment.
PD-1 expression on T-cell subsets in human HCC. We further analyzed the prevalence and phenotype of T-cell subsets within paired tumor tissues and surrounding liver tissues in patients with HCC (n = 20). We observed significant and comparable CD4 + and CD8 + T-cell infiltration in tumor tissues and surrounding liver tissues (Fig. 3A, top) . Because PD-1 is the coinhibitory signal receptor for B7-H1 and CD8 + cytotoxic T cells are the main effector in antitumor immune responses (4) (Fig. 3A,  bottom) . The percentage of PD-1 + CD8 + T cells was higher (63.0 F 20.3%) in tumor tissues than that in surrounding tissues (11.5 F 6.0%, P < 0.05; Fig. 3B and C) . The expression of PD-1 on CD8 + T cells in HCC tumor tissue (Fig. 3D, a) was confirmed by immunohistochemistry and was much higher than in surrounding nontumor (Fig. 3D, b) and normal liver tissues (Fig. 3D, c) . Cells were negative for staining with isotype control antibodies (Fig. 3D, d) . PD-1 + cells were also found to be localized primarily to the HCC stroma ( Supplementary Fig. S2 ). CD80, another reported receptor for B7-H1 (24), was not detected on CD8 + cells nor was B7-DC, another ligand for PD-1 (10), detected on KC or DC (data not shown). These results indicate that most of CD8 + T cells within human HCC are effector phenotype, with a greater percentage of these expressing PD-1 in the tumor microenvironment.
Functional characteristics of tumor-associated PD-1 + CD8 + T cells in human HCC. Given the high levels of PD-1 expression on CD8 + T cells in HCC, effector T cells might be functionally exhausted. We examined the functional characteristics of tumorassociated PD-1 + CD8 + T cells in human HCC. We initially compared the in vivo proliferation status of CD8 + T cells in tumor tissues versus surrounding liver tissues and of PD-1 + CD8 + T cells versus PD-1 À CD8 + T cells in human HCC using Ki67, a proliferative marker for cells in mitosis. The levels of Ki67 + CD8 + T cells were lower in tumor tissues than surrounding tissues (Fig. 4A) . Furthermore, PD-1
+ T cells were less proliferative than PD-1 À CD8 + T cells in patients with HCC (Fig. 4B) . PD-1 has previously been shown in animal models to negatively regulate CD8 + T-cell effector function (19, 20) . We further examined the functional markers of effector T cells, including cytokine profile and cytotoxic + T cells in HCC, human HCC tumor specimens were further analyzed by immunohistochemistry to determine their physical localization. A significant infiltration of B7-H1 + and PD-1 + cells was detected in the peritumor stroma when compared with the tumor nests ( Supplementary Fig. S2 ). In addition, B7-H1 + and PD-1 + cells seemed to be in close contact with each other, providing the possibility for direct interactions between these cells (Fig. 5A) (Fig. 5B ) and Ki67 expression (Fig. 5C ), T-cell effector cytokine expression, granzyme B expression, and perforin expression compared with no treatment isotype control group (Fig. 5C ). To evaluate whether B7-H1/PD-1 interactions affect tumor antigen-specific responses, we further performed HCCspecific IFNg enzyme-linked immunospot (ELISPOT) analysis using HCC-derived KCs loaded with HCC lysates to stimulate autologous HCC CD8 + T cells. Blocking B7-H1 or PD-1 using monoclonal antibodies increased the antigen-specific IFNg-secreting spots (Fig. 5D) 
CD14
+ cells from blood of healthy donors were used as control of tumor-associated KCs and showed similar results as the CD8 + T-cell alone cultures (data not shown) and were also similar to the mouse anti-human IgG1 isotype control (Fig. 5D) .
Discussion
An immune-suppressive environment has been previously described in patients with HCC comprising decreased numbers of CD8 + T cells and increased regulatory T cells (3, 25) . However, the underlying mechanisms controlling effector function remain poorly defined within human HCC. Furthermore, the nature and significance of B7-H1 and PD-1 in human HCC are likewise incompletely defined. In the current investigation, we have shown that HCC environmental factors stimulate B7-H1 expression on KCs and that the B7-H1/PD-1 pathway contributes to impaired effector T-cell function in the HCC environment.
B7-H1 has been reported to be expressed on multiple APC subsets (7, 8) . It has been shown that liver-resident pDCs or mDCs express B7-H1 after transplantation or virus infection (26, 27) . We found that in the HCC environment, B7-H1 expression is confined to KCs but is minimally expressed on mDCs, pDCs, or HCC tumor cells. A significant number of B7-H1 + KCs in HCC tissue were noted compared with surrounding nontumor tissue. Tumor-associated IL-10 contributed to B7-H1 up-regulation in the coculture system, and increased IL-10 expression was observed in human HCC. IL-10 expression was elevated in supernatants of monocytes and tumor cells when cocultured. Therefore, both tumor cells and macrophages in the HCC microenvironment could be the source of IL-10 following their interaction with each other. It is also possible that B7-H1 expression could be induced by other tumor-associated cytokines, such as IFNg and vascular endothelial growth factor (7, 15, 28) . Therefore, IL-10 may not the only factor inducing B7-H1 expression in the HCC microenvironment and is consistent with our previous findings in human ovarian carcinoma (15) . However, tumor-conditioned KCs are the likely mediator of B7-H1/PD-1 interactions in human HCC. CD8 + effector T cells mediate antitumor effects directly by expression of either antitumor cytokines (TNFa and IFNg) or cytotoxic granules (granzyme B and perforin). However, there was no significant difference in the prevalence of CD8 + T-cell distribution and effector phenotype between HCC tissue and surrounding nontumor tissue. Overexpression of PD-1 is a hallmark of exhausted T cells in chronic hepatitis (12, 29) . We showed in HCC tissue that higher percentages of CD8 + T cells express PD-1. These PD-1 +
CD8
+ T cells were mainly localized in the HCC stroma as opposed to the tumor nests. Several studies reported the importance of PD-1 expression in dampening antiviral CD8 + T-cell responses in human viral hepatitis (8, 9, 26) . Our results in HCC are consistent with these previous findings and are important, as chronic hepatitis or cirrhosis is a major risk factor for human HCC (1) . We have shown that PD-1 + CD8 + T cells in HCC also display impaired effector phenotype, indicating that the quality and function are altered in HCC.
Inhibitory B7-H1/PD-1 interaction can restrict immune responses against self-antigens. This pathway has emerged as a potential therapeutic target for treating cancer (13) (14) (15) (16) . In this study, we show that CD8 + T cells and KCs in human HCC tumor tissues expressed high levels of PD-1 and B7-H1, respectively, whereas other molecules (i.e., CD80 and B7-DC) were not detected. Exhausted CD8 + cells were able to be rescued following B7-H1 or PD-1 blockade using monoclonal antibodies, resulting in improved effector responses following TCR stimulation and stimulation with tumor-specific antigens. We have previously shown a role for B7-H1 to inhibit tumor immune responses in human ovarian carcinoma (15) . Other investigators have observed that blocking B7-H1/PD-1 enhances the function of antigen-specific T cells in infectious diseases (12, 28, 30, 31) .
To our knowledge, this is the first evidence that B7-H1 + APCs and PD-1 + T cells are physically localized in the same site of liver or within HCC and that T-cell effector function could be rescued by blocking B7-H1/PD-1 interactions, providing important therapeutic implications. By overall survival analysis, we observed that elevated B7-H1 expression in HCC is indeed associated with poorer prognosis in HCC patients as has been recently reported by other investigators (32) . Altogether, our data suggest that B7-H1/PD-1 interactions mediate immune suppression in human HCC and B7-H1 expression in tumor was associated with clinical outcome. The suppressive interaction between KCs and T cells using B7-H1/PD-1 interactions in HCC Figure 5 . B7-H1 + and PD-1 + cells were colocalized in HCC and mediated T-cell immune suppression. A, PD-1 + cells (green ) were colocalized with B7-H1 + cells (red ) and DAPI nuclear staining (blue ). Magnification, Â400. Representative data for eight patients. B and C, blocking B7-H1 or PD-1 increased T-cell effector function. CD14 + and CD8 + cells were sorted from human HCC and cocultured for 5 d with anti-CD3 and anti-CD28 antibodies. Where indicated, anti-PD-1 or anti-B7-H1 monoclonal antibodies were added and compared with control (mouse anti-human IgG1 isotype control for both anti-PD-1 and anti-B7-H1 antibodies). B, CD8 + T-cell proliferation was determined by [ 3 H]thymidine incorporation. Columns, mean counts per minute (CPM ) of five experiments; bars, SE. *, P < 0.05 versus isotype control. C, expression of Ki67, perforin, granzyme B, and cytokines was determined by FACS analysis with representative dot plots shown from five experiments. D, HCCspecific CD8 + T-cell response. CD8 + T cells were stimulated with KCs loaded with autologous HCC lysates over 5 d and HCC-specific IFNg was determined by ELISPOT in the presence or absence of anti-B7-H1 or anti-PD-1 antibody (n = 3 experiments). Columns, mean number of IFNg spots per 10 5 CD8 + T cells; bars, SE. *, P < 0.05 versus isotype control.
patients suggests that targeted therapies against this pathway represent a promising approach to enhance T-cell immunity to human HCC.
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